SuperworthMettler-Toledo International MTD
- Market cap
- $33.5B
- PE
- 37.6×
- 10y median 36.5×
- Forward PE
- 33.9×
- 10y median 32.6×
- Price to sales
- 8.1×
- EV/EBIT
- 30.5×
- Revenue, 12 months
- $4.1B
- +7% on a year ago
- Net margin
- 21.9%
- Free cash flow yield
- 2.6%
Mettler-Toledo International trades at 37.6× trailing earnings, near its ten-year median. Revenue was $4.1B over the last twelve months, up 7% on a year earlier with a 22% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $942.5M−4% | $935M−12% | $925.9M−0% | $946.8M−4% | $954.5M+1% | $1B+12% | $883.7M−5% | $983.2M+4% | $1B+8% | $1.1B+8% | $947.1M+7% | $1B+5% | |
| Cost of revenue | $382.9M−5% | $383.4M−10% | $377.8M−1% | $381.1M−4% | $382.1M−0% | $405.8M+6% | $357.9M−5% | $403.3M+6% | $420.2M+10% | $454.3M+12% | $391.3M+9% | $377.1M−7% |
| Gross profit | $559.5M−4% | $551.6M−13% | $548.1M+0% | $565.7M−3% | $572.5M+2% | $639.3M+16% | $525.9M−4% | $579.9M+3% | $609.5M+7% | $675.4M+6% | $555.8M+6% | $650.2M+12% |
| R&D | $46.1M+5% | $46.4M+1% | $46.4M+2% | $45.8M−3% | $47.1M+2% | $50.1M+8% | $46.3M−0% | $49.3M+8% | $51.1M+9% | $52.6M+5% | $51.3M+11% | $53M+8% |
| SG&A | $217.4M−7% | $223.4M−2% | $234.4M−0% | $235.8M+3% | $228.8M+5% | $237.3M+6% | $242.8M+4% | $247.3M+5% | $248.4M+9% | $259.8M+10% | $258.3M+6% | $263.3M+7% |
| $270.3M−6% | $250.6M−26% | $239.4M−2% | $260.6M−8% | $275.7M+2% | $331.6M+32% | $215.8M−10% | $262.2M+1% | $283.9M+3% | $338.8M+2% | $219.3M+2% | $309M+18% | |
| Interest expense | $20.3M+40% | $19.7M+17% | $19.2M+6% | $18.9M−2% | $18.6M−8% | $17.9M−9% | $16.7M−13% | $16.8M−12% | $17.7M−5% | $17.4M−3% | $17M+2% | $17.2M+3% |
| Pre-tax income | $251.2M−9% | $232.6M−28% | $220.5M−3% | $243.2M−8% | $259M+3% | $314.5M+35% | $201.9M−8% | $248.7M+2% | $269.2M+4% | $329.1M+5% | $209.7M+4% | $289.4M+16% |
| $49.5M−10% | $47.8M−19% | $43M+13% | $21.4M−57% | $47.4M−4% | $62.2M+30% | $38.4M−11% | $46.3M+117% | $51.7M+9% | $43.3M−30% | $40.2M+5% | $56.5M+22% | |
| Net income | $201.6M−9% | $184.8M−31% | $177.5M−6% | $221.8M+4% | $211.5M+5% | $252.3M+37% | $163.6M−8% | $202.3M−9% | $217.5M+3% | $285.8M+13% | $169.5M+4% | $232.9M+15% |
| $9.21−6% | $8.52−28% | $8.24−3% | $10.37+7% | $9.96+8% | $11.96+40% | $7.81−5% | $9.76−6% | $10.57+6% | $13.97+17% | $8.33+7% | $11.55+18% | |
| 21.9M−3% | 21.7M−3% | 21.5M−3% | 21.4M−3% | 21.2M−3% | 21.1M−3% | 20.9M−3% | 20.7M−3% | 20.6M−3% | 20.4M−3% | 20.3M−3% | 20.2M−3% |
Operating income: 60 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.1B | $1.1B to $1.1B | $12.12 | $12.09 to $12.16 | 7 |
| Q4 FY26 | $1.2B | $1.2B to $1.2B | $14.89 | $14.88 to $15.08 | 6 |
| Q1 FY27 | $990.8M | $984M to $1B | $10.01 | $9.92 to $10.14 | 2 |
| Q2 FY27 | $1.1B | $1.1B to $1.1B | $12.30 | $12.19 to $12.46 | 2 |
| Q3 FY27 | $1.1B | $1.1B to $1.1B | $13.26 | $13.15 to $13.44 | 2 |
| Q4 FY27 | $1.2B | $1.2B to $1.3B | $16.04 | $15.90 to $16.25 | 2 |
| Q1 FY28 | $1B | $1B to $1.1B | $12.33 | $12.22 to $12.49 | 5 |
| Q2 FY28 | $1.1B | $1.1B to $1.1B | $13.61 | $13.49 to $13.79 | 5 |
Peers
Companies in Medical - Diagnostics & Research nearest Mettler-Toledo International's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| Peer median | $33.7B | 39.3× | 33.8× | 27.8× | 6.4× | +8% | 8.9% |
Investors who own it
Investors we follow who held Mettler-Toledo International at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.3% of portfolioadded
More on Mettler-Toledo International
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 39Diagnostics and research stocks with the highest profit margins
- #5of 15Diagnostics and research stocks cheapest against their own PE history
- #9of 20Diagnostics and research stocks with the lowest PE ratio
- #9of 17Diagnostics and research stocks with the fastest earnings growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .